Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02411448
Recruitment Status : Active, not recruiting
First Posted : April 8, 2015
Last Update Posted : February 15, 2019
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company